Akari Therapeutics Reports Third Quarter Net Loss of $4.8 Million
Akari Therapeutics (AKTX) has released its financial results for the third quarter, reporting a net loss of $4.8 million. The announcement provides an update on the company's current fiscal standing as it continues its clinical and operational activities. The report highlights the ongoing burn rate typical of biotechnology firms in the development stage. While specific revenue drivers were not detailed in the brief release, the results reflect the company's current capital consumption during its research and development phase.
Tickers: $AKTX
Topics: financial results net loss quarterly earnings
Read the full article at Seeking Alpha
Part of the story Appili Therapeutics Reports First Half Net Loss of $3.5 Million (2 articles)